Veracyte outlines 2027 view with ~10% volume growth and 22% adjusted EBITDA, while resetting Decipher prostate to 12,000-15,000 incremental tests

The Quick Take
Read the full report from the original publisher.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents.
Related
Markets
Tucows Non-GAAP EPS of -$0.52, revenue of $100M
Markets
Ultralife GAAP EPS of $0.14, revenue of $48.3M
Markets
The world's best airline is updating its business and first-class experience
Singapore Airlines is rolling out new onboard seating, dining and entertainment options that are part of an over $2 billion Singapore dollar investment.
Markets
